Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

from Merck Serono following the completion of two phase 2 clinical trials for adecatumumab. Total operating expenses were $13.1 million for the three months ended December 31, 2007, compared to $10.9 million for the same period in 2006. For the three months ended December 31, 2007, Micromet reported a net loss of $3.8 million, or $0.09 per basic and diluted share, compared to net income of $3.4 million, or $0.11 per basic and diluted share, for the same period in 2006. The positive net income in 2006 was due primarily to the milestone payment received from Merck Serono.

Year Ended December 31, 2007

Revenues for the year ended December 31, 2007 were $18.4 million, compared to $27.6 million for 2006. For the year ended December 31, 2007, Micromet reported operating expenses of $43.6 million, compared to $61.2 million for the same period in 2006. In connection with the merger with CancerVax, Micromet recorded a non-recurring, non-cash charge of $20.9 million in the second quarter of 2006 due to the immediate write-off of CancerVax's in- process research and development programs. For the year ended December 31, 2007, net loss was $20.1 million, or $0.55 per basic and diluted share, compared to $34.0 million, or $1.29 per basic and diluted share, for 2006.

Micromet's cash and cash equivalents were $27.1 million as of December 31, 2007. Net cash used in operating activities was $14.3 million for the year ended December 31, 2007 and $15.4 million in 2006. Based on the status of our development programs, management believes that the cash balance at December 31, 2007 is sufficient to fund operations into the second quarter of 2009.

2008 Outlook:

-- Micromet will present an update on its proprietary BiTE antibody

technology platform and new BiTE antibody programs at the conference of

the American Association of Cancer Research (AACR) in April 2008.

-- A phase 1/2 clinical trial evaluating MT103 in patients wi
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... “2014 Deep Research Report ... is a professional and in-depth research report ... Polyurethane Resin basic information, including its definition, ... industry overview. This research covers the international ... well as global industry analysis covering macroeconomic ...
(Date:7/31/2014)... even the entire body to visualize long-range connections between ... a long-time dream of biologists. A study published by ... Cell has now made that dream a ... and human tissue biopsies transparent, while keeping the cellular ... way for a better understanding of brain-body interactions, more ...
(Date:7/31/2014)... , July 31, 2014 Rogne Bioscience, a ... Bay Area , has acquired a licence to ... commercialisation company. The potent anti-inflammatory activity of the peptides ... the University of Oxford,s Sir William Dunn School ... has raised over $1.5 million in seed financing, is ...
(Date:7/31/2014)... San Francisco, California (PRWEB) July 31, 2014 ... expert systems that inform therapeutic decision-making in oncology, today ... on August 14, 2014 to discuss the Company's financial ... to provide an update about the business in the ... live audio call beginning on Thursday, August 14, 2014, ...
Breaking Biology Technology:Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4See-through organs and bodies will accelerate biomedical discoveries 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2
... Spherix Incorporated,(Nasdaq: SPEX ) reported that the ... listing of its common stock from the Nasdaq,Global Market ... expected to,commence trading on the Nasdaq Capital Market on ... one of three market tier designations for,Nasdaq-listed stocks, and ...
... Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) announced today ... Sept. 30, 2008., Third Quarter and Nine Months ... nine months ended Sept. 30, 2008, was,$3.8 million and ... respectively in 2007. Revenue in the third quarter and ...
... ... Performance - ... PLYMOUTH MEETING, Pa., Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: ... the third quarter ended September,30, 2008. During the quarter, BMP Sunstone successfully ...
Cached Biology Technology:Spherix Transfers Stock Listing to Nasdaq Capital Market 2Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 2Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 3Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 4Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 5Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 6BMP Sunstone Reports Third Quarter 2008 Financial Results 2BMP Sunstone Reports Third Quarter 2008 Financial Results 3BMP Sunstone Reports Third Quarter 2008 Financial Results 4BMP Sunstone Reports Third Quarter 2008 Financial Results 5BMP Sunstone Reports Third Quarter 2008 Financial Results 6BMP Sunstone Reports Third Quarter 2008 Financial Results 7BMP Sunstone Reports Third Quarter 2008 Financial Results 8BMP Sunstone Reports Third Quarter 2008 Financial Results 9BMP Sunstone Reports Third Quarter 2008 Financial Results 10BMP Sunstone Reports Third Quarter 2008 Financial Results 11BMP Sunstone Reports Third Quarter 2008 Financial Results 12BMP Sunstone Reports Third Quarter 2008 Financial Results 13BMP Sunstone Reports Third Quarter 2008 Financial Results 14
(Date:7/31/2014)... follow-up study (HPV-023; NCT00518336) shows the sustained ... papilloma virus (HPV) vaccine Cervarix. Women vaccinated ... for more than nine years, and vaccine ... This is the longest follow-up report for ... for the full paper. , ...
(Date:7/31/2014)... 100 percent of animal models against the highly infectious ... an intestinal disease that kills approximately 30,000 Americans annually. ... Infection and Immunity . , In the study, ... the purified toxins produced by C. difficile , ... laboratory model that mimics the human disease, after only ...
(Date:7/31/2014)... Mont. In the same week that the U.S. ... of skin cancer, researchers at Montana State University published ... the genetic code in every cell responds when ... fundamental understanding of DNA damage by the UV rays ... cancer, aging and some degenerative eye diseases. , ...
Breaking Biology News(10 mins):Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3C. difficile vaccine proves safe, 100 percent effective in animal models 2New paper describes how DNA avoids damage from UV light 2New paper describes how DNA avoids damage from UV light 3
... more today than ever before about the microbes that inhabit ... gathering all of the relevant bits of information into one ... Now, grantees of the National Institute of Dental and ... and their international colleagues intend to solve this problem with ...
... investigating a radical new design for cargo ships that ... non-native creatures to sneak into the Great Lakes from ... been identified in the Great Lakes, and ballast water ... zebra and quagga mussels and two species of gobies. ...
... dispositions of strangers by observing others behavior and ... ability to recognize certain behavioral traits and make ... traits in strangers in similar situations thereafter. These ... George Washington University in Washington DC - and ...
Cached Biology News:Scientists launch first comprehensive database of human oral microbiome 2Scientists launch first comprehensive database of human oral microbiome 3U-M 'ballast-free ship' could cut costs while blocking aquatic invaders 2U-M 'ballast-free ship' could cut costs while blocking aquatic invaders 3Who's bad? Chimps figure it out by observation 2
... is a compact analysis system for the clinical ... a controller, advanced digital signal processing and a ... system includes the Luminex 100, the XY Platform, ... file at the FDA, and partner kits that ...
... nutritious peptone, used in ... of bacterial toxins, and ... bacteria with high nutritional ... Neisseria, Pasteurella, Salmonella and ...
... Ham's F12K medium with 2 mM L-glutamine and ... order to keep the antigens in their native ... are arrayed on a 12-well (5 mm) adhesive ... to enhance cellular attachment and to minimize background ...
Cell Culture Flask, 175 cm, tissue-culture treated polystyrene, barcoded...
Biology Products: